Jun 2026 (Q2 FY26) — Jul 23, 2026
IMAX Q2 FY26 — Record-Breaking Odyssey Performance Drives Strong Results
Read the full callIMAX earnings: last reported Thu, 23 Jul 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 103 | +12.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 20.2 | +4.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 15.4 | +36.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
1Y: $32.06 on 22 Oct 2025 → $53.38. High $56.33 (29 Sept 2026), low $31.7 (24 Oct 2025).
Overview
Call summaries
IMAX Q2 FY26 — Record-Breaking Odyssey Performance Drives Strong Results
Read the full callEvery analysed call
Financials
Net profit, year on year: +37% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 93 | 87 | 92 | 107 | 125 | 81 | 103 |
| Operating profit | 19 | 10 | 17 | 14 | 29 | 24 | 10 | 21 |
| Operating margin | 21.2% | 10.3% | 19.3% | 15.7% | 27.2% | 19.3% | 12.2% | 20.2% |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 18 | 8 | 15 | 13 | 28 | 7 | 8 | 19 |
| Tax rate | 13.4% | 17.5% | 47.2% | 8.9% | 18.7% | 61.8% | 28.5% | 18.1% |
| Net profit | 14 | 5 | 2 | 11 | 21 | 1 | 4 | 15 |
| EPS ($ per share) | 0.26 | — | 0.04 | 0.21 | 0.38 | — | 0.08 | 0.28 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 422 | 423 | 407 | 410 | 377 | 389 | 401 | 419 |
| Reserves | -85 | -40 | -203 | -235 | -293 | -293 | -275 | -240 |
| Total liabilities | 274 | 246 | 533 | 453 | 491 | 469 | 452 | 466 |
| Fixed assets | 281 | 307 | 277 | 260 | 253 | 243 | 240 | 243 |
| Total assets | 874 | 889 | 998 | 883 | 821 | 815 | 830 | 894 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 110 | 90 | -23 | 6 | 17 | 59 | 71 | 127 |
| Cash from investing | -57 | -66 | -9 | -0 | -53 | -32 | -41 | -42 |
| Cash from financing | -71 | -57 | 241 | -133 | -59 | -49 | -6 | -34 |
| Net cash flow | -17 | -32 | 208 | -128 | -92 | -21 | 24 | 51 |
| Capital expenditure | -13 | -7 | -1 | -4 | -8 | -6 | -8 | -8 |
| Free cash flow | 97 | 83 | -24 | 2 | 9 | 52 | 62 | 119 |
126 filings between Nov 7, 2025 and Sep 10, 2026.
Purchases
None
No insider bought shares.
Sales
$74.66M
31 sales by 9 insiders
45% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 16 conversions, 2 gifts.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| GELFOND RICHARD L | — | $42.56M | Aug 20, 2026 |
| DOUGLAS KEVIN | — | $21.48M | Mar 16, 2026 |
| WELTON MARK | — | $4.36M | Aug 25, 2026 |
| LISTER ROBERT D | — | $2.90M | Sep 10, 2026 |
| PABLO CALAMERA | — | $1.49M | Aug 20, 2026 |
| Fernandes Natasha | — | $1.19M | Aug 24, 2026 |
| Weissman Kenneth Ian | — | $436.3K | Aug 25, 2026 |
| Dolci Giovanni M. | — | $211.9K | Nov 10, 2025 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | LISTER ROBERT D Chief Legal Officer Sr Exec VP | Sale | 22,500 | $1.16M |
| Aug 25, 2026 | WELTON MARK President IMAX Global Theatres | Sale | 30,000 | $1.63M |
| Aug 25, 2026 | Weissman Kenneth Ian Deputy GC, Corp. Sec. & CCO | Sale | 8,000 | $436.3K |
| Aug 24, 2026 | Fernandes Natasha Chief Financial Officer & EVP | Sale | 20,000 | $1.09M |
| Aug 20, 2026 | PABLO CALAMERA CTO & EVP | Sale | 15,000 | $786.2K |
| Aug 20, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 100,000 | $5.32M |
| Aug 19, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 205,504 | $6.56M |
| Aug 19, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 205,504 | $10.95M |
| Aug 18, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 151,253 | $7.71M |
| Aug 18, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 151,253 | $4.82M |
| Aug 6, 2026 | Zlatar Jose Aleksandr SVP, Controller & PAO | Sale | 500 | $24.9K |
| Jun 11, 2026 | Pamon Steve Director | Option exercise | 3,390 | $0 |
| Jun 11, 2026 | DOUGLAS KEVIN Director | Award | 3,390 | $0 |
| Jun 11, 2026 | Berman Gail Director | Option exercise | 3,390 | $0 |
| Jun 11, 2026 | Throop Darren D Director | Tax withheld | 2,474 | $104.2K |
| Jun 11, 2026 | MacMillan Michael Director | Option exercise | 3,390 | $0 |
| Jun 11, 2026 | MacMillan Michael Director | Tax withheld | 1,849 | $77.9K |
| Jun 11, 2026 | Demirian Eric A Director | Tax withheld | 1,842 | $77.6K |
| Jun 11, 2026 | Demirian Eric A Director | Option exercise | 3,390 | $0 |
| Jun 11, 2026 | Wong Jennifer L. Director | Option exercise | 3,390 | — |
| Jun 11, 2026 | Throop Darren D Director | Option exercise | 4,611 | $0 |
| Jun 11, 2026 | LEEBRON DAVID W Director | Option exercise | 3,390 | $0 |
| Jun 11, 2026 | SETTLE DANA R Director | Option exercise | 3,390 | $0 |
| Apr 27, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 8,943 | $333.8K |
| Apr 27, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 8,943 | $280.8K |
| Apr 17, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 34,182 | $1.07M |
| Apr 17, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 34,182 | $1.27M |
| Apr 16, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 41,737 | $1.31M |
| Apr 16, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 41,737 | $1.55M |
| Apr 15, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 15,746 | $583.7K |
| Apr 15, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 15,746 | $494.4K |
| Apr 14, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 6,924 | $217.4K |
| Apr 14, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 6,924 | $256.7K |
| Apr 13, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 97,462 | $3.06M |
| Apr 13, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 97,462 | $3.62M |
| Apr 10, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 135,046 | $5.11M |
| Apr 10, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 135,046 | $4.24M |
| Apr 6, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 12,987 | $522.9K |
| Apr 6, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 12,987 | $407.8K |
| Apr 2, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion 10b5-1 plan | 12,037 | $378.0K |
| Apr 2, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale 10b5-1 plan | 12,037 | $481.5K |
| Mar 16, 2026 | DOUGLAS KEVIN Director | Sale | 43,800 | $1.66M |
| Mar 16, 2026 | DOUGLAS KEVIN Director | Sale | 43,800 | $1.66M |
| Mar 16, 2026 | DOUGLAS KEVIN Director | Sale | 43,800 | $1.66M |
| Mar 16, 2026 | DOUGLAS KEVIN Director | Sale | 43,800 | $1.66M |
| Mar 16, 2026 | DOUGLAS KEVIN Director | Sale | 62,600 | $2.37M |
| Mar 16, 2026 | DOUGLAS KEVIN Director | Sale | 330,200 | $12.49M |
| Mar 10, 2026 | GELFOND RICHARD L Chief Executive Officer | Conversion | 121,220 | $3.81M |
| Mar 10, 2026 | GELFOND RICHARD L Chief Executive Officer | Sale | 121,220 | $4.86M |
| Mar 7, 2026 | Manwaring Daniel CEO, IMAX China Holding, Inc. | Tax withheld | 4,790 | $195.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow IMAX CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading